dEjournals Home Page
Régiókutatás Szemle
Current
Archives Fortcoming Articles Search
Register Login

Régiókutatás Szemle

Vol. 8 No. 1 (2023)
Articles

Examining macro factors influencing human capital investment decisions in the pharmaceutical industry

Published:
February 5, 2024
DOI Linkhttps://doi.org/10.30716/RSZ/23/1/2
Author
Gergő Tömöri
View
hu
Keywords
Human capital Macro-environment Pharmaceutical industry Innovation
License

Copyright (c) 2023 Gergő Tömöri

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

How To Cite
Selected Style: APA
Tömöri, G. (2024). Examining macro factors influencing human capital investment decisions in the pharmaceutical industry. Régiókutatás Szemle, 8(1), 10-20. https://doi.org/10.30716/RSZ/23/1/2
Abstract

The innovation policies of the pharmaceutical industry are determined mainly by elements of the macro-environment that influence the strategic directions of the companies. In this context, the study aimed to examine whether and to what extent determined the expansion or reduction of the workforce of pharmaceutical companies in the last decade by macro-environmental indicators. These indicators represent the political, economic, social and technological innovation environment well, which are also considered their strategic decisions. The analysis was based on sectoral and macroeconomic indicators and industry employment data for 27 European countries. The results of the multivariate statistical analysis show that the economic potential of each country's uptake market, the volume of governmental support, and the human development index significantly influenced the evolution of pharmaceutical employment over the period under study.

References
  1. Abdullah, M. N., Shamsher R. (2011): A Study on the Impact of PEST Analysis on the Pharmaceutical Sector: The Bangladesh Context. Journal of Modern Accounting and Auditing, Vol. 7 (No. 12), pp. 1446-1456.
  2. Asen, E. (2021): Tax Subsidies for R&D Expenditures in Europe. Tax foundation. Online availability: https://taxfoundation.org/rd-tax-incentives-europe-2021/ 2023.05.10.
  3. Becsky-Nagy P., Fazekas B. (2023): Spurring entrepreneurship with public venture capital in developing industries – evidence from Hungary. Journal of Entrepreneurship in Emerging Economies. DOI: 10.1108/JEEE-06-2022-0167
  4. JOURNAL OF ENTREPRENEURSHIP IN EMERGING ECONOMIES ahead-of-print : ahead-of-print Paper: 10.1108/JEEE-06-2022-0167 (2023)
  5. Becker K. (2009): Pharma patents in Europe: where are we going? Future Medicinal Chemistry, Vol. 1 (No. 2), pp. 227-230. ISSN: 1756-8919. DOI:10.4155/fmc.09.19
  6. Bramhandkar, A., Erickson, S., Applebee, I. (2007): Intellectual capital and organizational performance: an empirical study of the pharmaceutical industry. The Electronic Journal of Knowledge Management Vol. 5 (No. 4): pp. 357 – 362. DOI: 10.4236/cn.2017.91001
  7. Brown, R. S. (2015): Strategic intent, capabilities and financial performance: A study of the pharmaceutical industry. Journal of Management Policy and Practice, Vol. 16 (No. 1): pp. 18-30.
  8. Ding M., Eliashberg J., Stremersch S. (2014): The Pharmaceutical Industry: Specificity, Challenges. In: Innovation and Marketing in the Pharmaceutical Industry. Emerging Practices, Research, and Policies. Springer, pp. 2-18.
  9. Dogramatzis D. (2002): Pharmaceutical Marketing. A Practical Guide. Taylor & Francis Group, pp. 23-42.
  10. Fazekas B., Becsky-Nagy P. (2019): Mit jelez a tulajdonosi szerkezet? – A tulajdonosi szerkezet és a vállalkozások teljesítményének kapcsolata információs aszimmetriák mellett a magyarországi kockázatitőke-befektetések tükrében. Vezetéstudomány. Vol. 50, (No. 7-8): pp. 31-38. DOI: 10.14267/VEZTUD.2019.07.03
  11. Gottinger H. (2010): European Biotech-pharma Industry Development. In: Biotechnology In Agriculture, Industry And Medicine. Strategic alliances in biotechnology and pharmaceuticals (Hans – Umali). Nova Science Publishers, New York, pp. 73-88.
  12. Henderson R.,Cockburn I. (1994): Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal, Vol. 15: pp. 63-84. DOI: 10.1002/smj.4250150906
  13. Henry, D., Lexchin, J. (2002): The pharmaceutical industry as a medicines provider. The Lancet, Vol. 360: pp. 1590-1595. DOI: 10.1016/S0140-6736(02)11527-3
  14. Hudec, O., Prochádzková, M. (2015): Visegrad Countries and regions: innovation performance and efficiency. Quality Innovation Prosperity, Vol. 19 (No. 2): pp. 55-71. DOI: 10.12776/qip.v19i2.593
  15. Hutton, J., Borowitz, M., Oleksy, I., Luce, B.R. (1994): The pharmaceutical industry and health reform: lessons from Europe. Health Affairs, Vol. 13 (No. 3): pp. 98-111. DOI: 10.1377/hlthaff.13.3.98
  16. Xu, Jianwei (2017): Pharmaceutical industry at risk from Brexit. Bruegel. Online availability: https://www.bruegel.org/blog-post/pharmaceutical-industry-risk-brexit 2023.05.07.
  17. Jørgensen, L. F. (2022): Why does pharmaceutical innovation in Europe matter for jobs and growth? Politico. Online availability: https://www.politico.eu/sponsored-content/why-does-pharmaceutical-innovation-in-europe-matter-for-jobs-and-growth/#_ftn2 2023.05.06.
  18. Kovács, Zs. I. (2018): Innovation and sustainability: disclosure practices of Hungarian pharmaceutical companies. Journal of Accounting and Management, Vol. 8 (No. 2): pp. 129-140
  19. Kremer, M. (2002): Pharmaceuticals and the Developing World. Journal of Economic Perspectives, Vol. 16 (4): pp. 67-90. DOI: 10.1257/089533002320950984
  20. Lengyel, B., Cadil, V. (2009): Innovation policy challenges in transition countries: foreign business R&D in the Czech Republic and Hungary. Transition Studies Review. DOI: 10.1007/s11300-009-0046-5
  21. Lindstone J., Maclennan J. (1999): Marketing Planning for the Pharmaceutical Industry. Second Edition. Taylor & Francis Group, pp. 15-37.
  22. Maclennan, J. (2004): Brand Planning for the Pharmaceutical Industry. Taylor & Francis Group, pp. 19-31. ISBN: 0566085208
  23. Mazzucato M., Parris S. (2015): High-growth firms in changing competitive environments: the US pharmaceutical industry (1963 to 2002). Small Business Economics, Vol. 44, pp. 145–170. DOI: 10.1007/s11187-014-9583-3
  24. Molendowski, E., Żmuda, M. (2013): Changes in competitiveness among the Visegrad Countries after accession to the European Union: A comparative analysis based on a generalized double Diamond Model. Comparative Economic Research, Vol. 16. (No. 4): pp. 121-153. DOI: 10.2478/cer-2013-0031
  25. Mrazek M. F. (2002): Comparative Approaches to Pharmaceutical Price Regulation in the European Union. Croatian Medical Journal, Vol. 43 (No. 4): pp. 453-461.
  26. Nirkisch, K. J., Greuel, J. M., Bode-Greuel, K. M. (2009): How can pharmaceutical and biotechnology companies maintain a high profitability? Journal of Commercial Biotechnology, Vol. 15, pp. 309–323. DOI: 10.1057/jcb.2009.3
  27. Owczarczuk, M. (2013): Government Incentives and FDI into R&D. The Case of Visegrad Countries. Entrepreneurial Business and Economics Review, Vol. 1. (No. 2): pp. 73‐86.
  28. Powell, W.W. (1998): Learning from collaboration: knowledge and networks in the biotechnology and pharmageutigal industries. California management review, Vol. 40. (No. 3): pp. 228-240. DOI: 10.2307/41165952
  29. Rollins B. L., Perri M. (2014): Pharmaceutical Marketing. Jones & Bartlett Learning, pp. 30-49.
  30. Roser M. (2019): Human Development Index. Online source: https://ourworldindata.org/ 2023.05.05.
  31. Wojciechowski, L. (2013): The Determinants of FDI Flows from the EU‐15 to the Visegrad Group Countries – A Panel Gravity Model Approach. Entrepreneurial Business and Economics Review, 1. szám (No. 1): pp. 7‐22.
Database Logos
DOAJ ProQuest MTMT SHERPA EIRHPLUS EBSCO CROSSREF